UNSPSC 51313204: Diphenylpyraline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 33361OE3AV, chemically known as piperidine, 4- (diphenylmethoxy)-1-methyl-, hydrochloride but generally known as diphenylpyraline, which bears US NIH Compound Identifier 3103. European Medicines Agency schedules Diphenylpyraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07213MIG.

UNSPSC 51313204 Diphenylpyraline is a Commodity code that captures individual pharmaceutical products and active pharmaceutical ingredients purchased by state and local health agencies, typically through health departments, county public health offices, and state HHS commissions. The code sees activity primarily around generic pharmaceuticals, OTC products, and specialized health intervention supplies—naloxone, drug deactivation systems, and multi-source generics—rather than diphenylpyraline specifically. State and local buyers procure these products through competitive bidding (IFB), requests for proposal (RFP), and cooperative purchasing arrangements to support community health programs, pharmacy benefit initiatives, and emergency response stockpiles. Issuing bodies include county health departments, state HHS commissions, and multi-state cooperative purchasing alliances that aggregate demand across multiple jurisdictions and subordinate agencies.

Recent activity clusters in Florida and Texas, with broader multi-state reach through cooperative vehicles. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs serving state pharmacy benefit plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, seeking multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. MMCAP requires vendors to work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) and evaluates submissions 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative fee format compliance, EDI capability, and fee agreement.